Literature DB >> 21552268

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Nicolas F Delahaye1, Sylvie Rusakiewicz, Isabelle Martins, Cédric Ménard, Stephan Roux, Luc Lyonnet, Pascale Paul, Matthieu Sarabi, Nathalie Chaput, Michaela Semeraro, Véronique Minard-Colin, Vichnou Poirier-Colame, Kariman Chaba, Caroline Flament, Véronique Baud, Hélène Authier, Saadia Kerdine-Römer, Marc Pallardy, Isabelle Cremer, Laetitia Peaudecerf, Bénédita Rocha, Dominique Valteau-Couanet, Javier Celis Gutierrez, Jacques A Nunès, Frédéric Commo, Sylvie Bonvalot, Nicolas Ibrahim, Philippe Terrier, Paule Opolon, Cristina Bottino, Alessandro Moretta, Jan Tavernier, Pascal Rihet, Jean-Michel Coindre, Jean-Yves Blay, Nicolas Isambert, Jean-François Emile, Eric Vivier, Axel Lecesne, Guido Kroemer, Laurence Zitvogel.   

Abstract

The natural killer (NK) cell receptor NKp30 is involved in the recognition of tumor and dendritic cells (DCs). Here we describe the influence of three NKp30 splice variants on the prognosis of gastrointestinal sarcoma (GIST), a malignancy that expresses NKp30 ligands and that is treated with NK-stimulatory KIT tyrosine kinase inhibitors. Healthy individuals and those with GIST show distinct patterns of transcription of functionally different NKp30 isoforms. In a retrospective analysis of 80 individuals with GIST, predominant expression of the immunosuppressive NKp30c isoform (over the immunostimulatory NKp30a and NKp30b isoforms) was associated with reduced survival of subjects, decreased NKp30-dependent tumor necrosis factor-α (TNF-α) and CD107a release, and defective interferon-γ (IFN-γ) and interleukin-12 (IL-12) secretion in the NK-DC cross-talk that could be restored by blocking of IL-10. Preferential NKp30c expression resulted partly from a single-nucleotide polymorphism at position 3790 in the 3' untranslated region of the gene encoding NKp30. The genetically determined NKp30 status predicts the clinical outcomes of individuals with GIST independently from KIT mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21552268     DOI: 10.1038/nm.2366

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  43 in total

1.  A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC.

Authors:  M J Neville; R D Campbell
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse.

Authors:  Tao Xie; Lee Rowen; Begoña Aguado; Mary Ellen Ahearn; Anup Madan; Shizhen Qin; R Duncan Campbell; Leroy Hood
Journal:  Genome Res       Date:  2003-12       Impact factor: 9.043

3.  Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Authors:  Cédric Ménard; Jean-Yves Blay; Christophe Borg; Stefan Michiels; François Ghiringhelli; Caroline Robert; Céline Nonn; Nathalie Chaput; Julien Taïeb; Nicolas F Delahaye; Caroline Flament; Jean-François Emile; Axel Le Cesne; Laurence Zitvogel
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

4.  Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients.

Authors:  Andrea De Maria; Manuela Fogli; Stefania Mazza; Monica Basso; Antonio Picciotto; Paola Costa; Sonia Congia; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Eur J Immunol       Date:  2007-02       Impact factor: 5.532

5.  NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Authors:  Massimo Vitale; Mariella Della Chiesa; Simona Carlomagno; Daniela Pende; Maurizio Aricò; Lorenzo Moretta; Alessandro Moretta
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

6.  Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals.

Authors:  Erik Rutjens; Stefania Mazza; Roberto Biassoni; Gerrit Koopman; Luana Radic; Manuela Fogli; Paola Costa; Maria Cristina Mingari; Lorenzo Moretta; Jonathan Heeney; Andrea De Maria
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors:  Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

9.  Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

Authors:  M J Robertson; K J Cochran; C Cameron; J M Le; R Tantravahi; J Ritz
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

10.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more
  159 in total

1.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 2.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

3.  NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.

Authors:  Elke Pogge von Strandmann; Olga Shatnyeva; Hinrich P Hansen
Journal:  Ann Transl Med       Date:  2015-11

4.  Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases.

Authors:  Ming Wang; Jia Xu; Wenyi Zhao; Lin Tu; Weiqing Qiu; Chaojie Wang; Yangyin Shen; Qiang Liu; Hui Cao
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

6.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

7.  In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation.

Authors:  Yoojin Lee; Heewook Shin; Jongsun Kim
Journal:  J Innate Immun       Date:  2020-09-16       Impact factor: 7.349

8.  Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma.

Authors:  Fabio Morandi; Loredana Amoroso; Alessandra Dondero; Roberta Castriconi; Stefano Parodi; Roberto Luksch; Fiorina Casale; Aurora Castellano; Alberto Garaventa; Alessandro Moretta; Cristina Bottino; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

9.  The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Authors:  Sonja Textor; Felicitas Bossler; Kai-Oliver Henrich; Moritz Gartlgruber; Julia Pollmann; Nathalie Fiegler; Annette Arnold; Frank Westermann; Nina Waldburger; Kai Breuhahn; Sven Golfier; Mathias Witzens-Harig; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-07-28       Impact factor: 8.110

10.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.